Multimodality Treatment Including Curative Resection of Advanced NSCLC

July 2, 2020 updated by: Katharina Sinn, Medical University of Vienna

Multimodality Treatment Including Curative Resection of Advanced Stage Non-small Cell Lung Cancer - an Explorative, Retrospective Pilot Study

This study retrospectively evaluates clinical parameters and outcome of patients with advanced stage non-small cell lung cancer treated with neoadjuvant therapy followed by curative-intent surgery at the Divison of Thoracic Surgery at the Medical University of Vienna

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This study will be undertaken as a retrospective cohort study at Devision of Thoracic Surgery, Medical University of Vienna. All patients with non-small-cell lung cancer, who received an induction chemo- or chemoradiotherapy followed by surgery in a curative intention at the Devision of Thoracic Surgery, Medical University, will be included. The aim of this study is to evaluate peri- and postoperative clinical parameters and short- and long-term outcomes in patients.

Study Type

Observational

Enrollment (Anticipated)

190

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Austria
      • Vienna, Austria
        • Recruiting
        • Medical University of Vienna
        • Contact:
          • Katharina Sinn, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients with non-small-cell lung cancer, who received an induction chemo- or chemoradiotherapy followed by surgery in a curative intention at the Devision of Thoracic Surgery, Medical University.

Description

Inclusion Criteria:

  • Patients with advanced NSCLC and multimodality treatment including curative-intent resection

Exclusion Criteria:

  • Patients with early stage NSCLC
  • Patients with advanced NSCLC without multimodality treatment
  • Patients without curative resection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Neoadjuvant chemoradiotherapy
Patients with advanced NSCLC treated with neoadjuvant platinum-based chemoradiotherapy followed by curative-intent surgery
Other: Date collection
Retrospective data analysis
Neoadjuvant chemotherapy
Patients with advanced NSCLC treated with neoadjuvant platinum-based chemotherapy followed by curative-intent surgery
Other: Date collection
Retrospective data analysis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival
Time Frame: 18 years
  • Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery
  • Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery
  • Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery
18 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Vienna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2017

Primary Completion (Anticipated)

August 1, 2020

Study Completion (Anticipated)

August 1, 2020

Study Registration Dates

First Submitted

June 29, 2020

First Submitted That Met QC Criteria

June 29, 2020

First Posted (Actual)

July 2, 2020

Study Record Updates

Last Update Posted (Actual)

July 7, 2020

Last Update Submitted That Met QC Criteria

July 2, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 193132122

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Advanced Non-small-cell Lung Cancer

Clinical Trials on Date collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe